OOIR: Observatory of International Research

Papers

(The H4-Index of Arthritis & Rheumatology is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
	724
CCL19‐Positive Lymph Node Stromal Cells Govern the Onset of Inflammatory Arthritis via Tropomyosin Receptor Kinase	268
Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis	205
	185
Assessing the Immune Cell Subset and Genetic Mutations in Patients With Palindromic Rheumatism Seronegative for Rheumatoid Factor and Anti–Cyclic Citrullinated Peptide	151
No differences in myocardial perfusion between treatment‐naive, early rheumatoid arthritis patients and healthy controls	148
Seronegative palindromic rheumatism: what are we talking about? Comment on the article by Yang et al	142
The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID‐19 Era	141
At the Heart of Treating Kawasaki Disease: The Search for New Approaches to Prevent Coronary Artery Aneurysms	129
Association of change in metabolic syndrome status with altered risk of incident gout: comment on the article by Eun et al	127
The Devil Is in the Detail: Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty	117
Targeting the Myddosome in Systemic Autoimmunity: Ready for Prime Time?	114
Pregnancy Outcomes in Women With Psoriatic Arthritis in Relation to Presence and Timing of Antirheumatic Treatment	105
Possible confounding factors explaining data on heart failure risk in patients with polymyositis/dermatomyositis: comment on the article by Lin et al	104
Clinical Images: Rice bodies in pseudogout	104
Using Mice to Model Human Osteoarthritis: Age, Biologic Sex, and Pain Matter	102
Higher alcohol consumption was associated with greater incidence of total hip replacement due to hip osteoarthritis in a dose‐dependent manner in women: comment on the article by Marchand et al	101
COVID‐19 vaccine uptake and vaccine hesitancy in rheumatic disease patients receiving immunomodulatory therapies in community practice settings	98
Reply	96
Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (PRESTO): A Step Towards Prevention	93
Disturbed Spatial WNT Activation—A Potential Driver of the Reticularized Skin Phenotype in Systemic Sclerosis	90
Incidence, Prevalence, and Mortality of Lupus Nephritis: A Population‐Based Study Over Four Decades Using the Lupus Midwest Network	87
Interleukin‐13 Receptor α1–Mediated Signaling Regulates Age‐Associated/Autoimmune B Cell Expansion and Lupus Pathogenesis	82
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases	82
Contribution of Interleukin‐4–Induced Epithelial Cell Senescence to Glandular Fibrosis in IgG4‐Related Sialadenitis	81

Gut Microbiome and Osteoarthritis: Insights From the Naturally Occurring Canine Model of Osteoarthritis	79
Role of Glutaminase 2 in Promoting CD4+ T Cell Production of Interleukin‐2 by Supporting Antioxidant Defense in Systemic Lupus Erythematosus	78
NLRP3 Attenuates Intraocular Inflammation by Inhibiting AIM2‐Mediated Pyroptosis Through the Phosphorylated Salt‐Inducible Kinase 1/Sterol Regulatory Element Binding T	78
A methodologic problem and a conceptual issue related to the new 2022 antineutrophil cytoplasmic antibody–related vasculitis criteria sets: comment on criteria sets approved by the American College of	78
Endogenous Retroelement Activation is Implicated in Interferon‐α Production and Anti–Cyclic Citrullinated Peptide Autoantibody Generation in Early Rheumatoid Arthritis	74
Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy	72
Identification of Shared and Asian‐Specific Loci for Systemic Lupus Erythematosus and Evidence for Roles of Type III Interferon Signaling and Lysosomal Function in the Disease: A	71
Efficacy and Safety of ABBV‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with Moderate‐to‐Severe Rheumatoid Arthr	70
Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial	66
Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus	62
Knee Alignment Correction by High Tibial Osteotomy Reduces Symptoms and Synovial Inflammation in Knee Osteoarthritis Accompanied by Macrophage Phenotypic Change From M1 to M2	62
The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial	61
Alteration of Gut Microbiota in Individuals at High‐Risk for Rheumatoid Arthritis Associated With Disturbed Metabolome and the Initiation of Arthritis Through the Triggering of Mucosal Immu	60
Reply	58
Minimal tofacitinib dose for maintenance in axial spondyloarthritis: real‐world data from a resource‐limited setting	56
A randomized, double‐blind, placebo‐controlled trial of abatacept for the treatment of relapsing, non‐severe, granulomatosis with polyangiitis	56
In This Issue	54
Clinical Connections	53
In This Issue	53
Clinical Connections	52
Systemic lupus erythematosus and atherosclerosis progression risk: comment on the article by Papazoglou et al.	52
Correction to “Novel Genetic Loci in Early‐Onset Gout Derived From Whole‐Genome Sequencing of an Adolescent Gout Cohort”	51
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Tr	51
Sex Differences in B Cells From the Joints of Children With Oligoarticular Juvenile Idiopathic Arthritis	51
The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria	50
Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis	50